SLC5A2 and myocardial infarction: Apart from 3 trials [18, 22, 27], thirteen studies evaluated the occurrence of myocardial infarction (SGLT2 inhibitors, 19,747 patients, 200 events; placebo, 16,949 patients, 186 events).